3rd Due Diligence Summit for Life Sciences – 3rd Due Diligence Summit for Life Sciences
Recent years have shown a rise in development across the generic and biosimilar industries, as many blockbuster products near the end of their patents. The need to expand the reach of R&D programs has driven major new investments in co-development, strategic alliances, licensing and acquisitions, with big pharmaceutical companies scrambling to maintain their strongholds on specific therapeutic areas. This has increased the need for a robust due diligence process across all functions, as companies look to external targets as a means of supplementing pipelines and bolstering their product portfolios.
The 3rd Due Diligence Summit for Life Sciences will provide an overview of the proven strategies and insights of due diligence leaders from medical device, biotechnology and pharmaceutical companies and discuss how best to maneuver the rapidly changing landscape of the industry.
Top Reasons to Attend
EXPLORE BEST PRACTICES for companies of all sizes looking to acquire or in-license a product
GAIN valuable insight from cross-functional due diligence team members, as well as leaders in the medical device and biotech industries
UNDERSTAND how to conduct a comprehensive intellectual property due diligence investigation, and how it can alter the strategy for your deal
LEARN how to evaluate and effectively manage strategic alliances through case studies from industry leaders
ASSESS the regulatory and compliance standards of a target and how gaps can lead to unforeseen financial burdens
HEAR FROM ADDITIONAL FEATURED SPEAKERS representing Zimmer Biomet, Insightra Medical, Analogic Corporation, Boehringer Ingelheim, Bayer, G&W Laboratories, Elanco and other organizations!
Who Should Attend
This conference is designed for representatives from pharmaceutical, medical device and biotechnology companies with responsibilities in the following areas: